Catalyst
Slingshot members are tracking this event:
Lannett (LCI) Receives FDA Approval for Buprenorphine and Naloxone Sublingual Tablets in Treatment of Opioid Addiction
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LCI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda Approval, Buprenorphine, Naloxone, Sublingual Tablets, Opioid Addiction
